Saquinavir indications and usage: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Saquinavir }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INVIRASE (SAQUINAVIR MESYLATE) CAPSULE INVIR...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Indications And Usage== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INVIRASE (SAQUINAVIR MESYLATE) CAPSULE INVIRASE (SAQUINAVIR MESYLATE) TABLET, FILM COATED [GENENTECH, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a | publisher = | date = | accessdate = }}</ref> | INVIRASE in combination with ritonavir and other antiretroviral agents is indicated for the treatment of HIV-1 infection in adults (over the age of 16 years). | ||
The following points should be considered when initiating therapy with INVIRASE: | |||
*The twice daily administration of INVIRASE in combination with ritonavir is supported by safety data from the MaxCmin 1 trial [see Adverse Reactions (6.1)] and pharmacokinetic data [see Clinical Pharmacology ]. | |||
*The efficacy of INVIRASE with ritonavir has not been compared against the efficacy of antiretroviral regimens currently considered standard of care. | |||
*The number of baseline primary protease inhibitor mutations affects the virologic response to INVIRASE/ritonavir<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INVIRASE (SAQUINAVIR MESYLATE) CAPSULE INVIRASE (SAQUINAVIR MESYLATE) TABLET, FILM COATED [GENENTECH, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a | publisher = | date = | accessdate = }}</ref> | |||
Latest revision as of 16:17, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications And Usage
INVIRASE in combination with ritonavir and other antiretroviral agents is indicated for the treatment of HIV-1 infection in adults (over the age of 16 years).
The following points should be considered when initiating therapy with INVIRASE:
- The twice daily administration of INVIRASE in combination with ritonavir is supported by safety data from the MaxCmin 1 trial [see Adverse Reactions (6.1)] and pharmacokinetic data [see Clinical Pharmacology ].
- The efficacy of INVIRASE with ritonavir has not been compared against the efficacy of antiretroviral regimens currently considered standard of care.
- The number of baseline primary protease inhibitor mutations affects the virologic response to INVIRASE/ritonavir[1]
References
Adapted from the FDA Package Insert.